No profile data available.
Maravai LifeSciences Holdings, Inc. (MRVI) is a healthcare company in the additional production service providers industry, based in San Diego, United States, with about 415 full-time employees.
It reported revenue of $185.74 million for fiscal year 2025, down 28.3% from fiscal year 2024, and net income of -$130.77 million. Its largest business segment, TriLink, brought in 64% of segment revenue in fiscal year 2025; North America was the largest region with 61%. Its market capitalization was $2.76 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Maravai LifeSciences reported $185.74 million in revenue for fiscal year 2025, down 28.3% from $259.19 million in fiscal year 2024.
TriLink, with $119.79 million or 64% of segment revenue in fiscal year 2025. Next: Cygnus (36%).
North America: 61% of revenue by region in fiscal year 2025, followed by Asia Pacific (22%).
$2.76 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional production service providers) include DSwiss, Inc. (DQWS), Bio Essence Corporation (BIOE), Natural Alternatives International, Inc. (NAII), Integrated BioPharma, Inc. (INBP).